Keryx Biopharmaceuticals
21
0
1
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
19.0%
4 terminated/withdrawn out of 21 trials
78.9%
-7.6% vs industry average
67%
14 trials in Phase 3/4
93%
14 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (21)
Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
Role: lead
Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease
Role: lead
A Study of Ferric Citrate to Improve Inflammation and Lipid Levels
Role: collaborator
Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients
Role: collaborator
Effect of Sulodexide in Overt Diabetic Nephropathy
Role: lead
KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)
Role: lead
Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas
Role: collaborator
Ferric Citrate in ESRD Pilot Project
Role: collaborator
A Pilot Study of KRX-0502 (Ferric Citrate, Administered Without Food, in Treating Iron-deficiency Anemia
Role: lead
Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D
Role: collaborator
Effect of Sulodexide in Early Diabetic Nephropathy
Role: lead
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
Role: lead
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
Role: lead
A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)
Role: lead
Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong
Role: lead
A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis
Role: lead
Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer
Role: collaborator
A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis
Role: lead
Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
Role: lead
A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
Role: lead